S-1 plus CDDP
Phase 3Small molecule
Taiho Pharmaceutical Co., Ltd.S-1 plus CDDP is one of 83 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.
3
Indications
3
Total Trials
0
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
714 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Xeloda
RochePhase 3
S-1 plus CDDP
Taiho Pharmaceutical Co., Ltd.Phase 3
Gemzar
Johnson & JohnsonPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
S1,
CChinese Academy of Medical Sciences
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Induction Phase1
GenmabPreclinical
Glutamine
SanofiPreclinical
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Preclinical
CEA-Targeted CAR-T Cells
CChongqing Precision Biotech Co., Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for S-1 plus CDDP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details